Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of lymphoproliferative disorders originating in B-lymphocytes, T-lymphocytes, or natural killer (NK) lymphocytes. An estimated 63,190 new cases of NHL, including 34,200 in men and 28,990 in women, will be diagnosed in 2007, and 18,660 deaths will occur. NHL is the fifth leading type of new cancer diagnosed and the ninth leading cause of cancer deaths among men and the seventh among women. The median age of individuals with NHL has risen in the past 2 decades, resulting in a patient population that may also have significant comorbid conditions, complicating treatment options. Important updates to these guidelines for 2008 include expanded second-line therapy options for patients with diffuse large B-cell lymphoma and those with peripheral T-cell lymphomas. In addition, the mycosis fungoides/Sézary syndrome section now includes pages on updated staging and classification systems and suggested treatment regimens.
For the most recent version of the guidelines, please visit NCCN.org
If the inline PDF is not rendering correctly, you can download the PDF file here.
Since 1996, Dana-Farber/Brigham and Women's Cancer Center and Massachusetts General Hospital Cancer Center have combined their extensive clinical research and training programs into a single, fully integrated program. This partnership has fostered a greater exchange of ideas, improved the efficiency and speed with which discoveries can make their way from the laboratory bench to the patient's bedside, and created a robust training program for future physician-investigators. With more than 460 clinical studies currently underway, patients have greater access to promising new therapies, while physician-scientists are better able to gain and share valuable insights that may lead to advances in cancer treatment for all. Through a comprehensive clinical training program, fellows work alongside leading specialists at one of the largest sites for the evaluation and treatment of cancer in the nation, which prepares them to become the future leaders in clinical and laboratory investigating and clinical teaching. The collaboration between Dana-Farber/Brigham and Women's Cancer Center and Massachusetts General Hospital Cancer Center represents two extraordinary institutions working toward a common goal of eliminating cancer in its many forms. Together they strive to become a model for superlative patient care, research, and training.
Edward J. Benz, Jr., MD (second photo on the cover), is Chief Executive Officer of Dana-Farber/Partners CancerCare, the adult oncology collaboration of Dana-Farber/Brigham and Women's Cancer Center and Massachusetts General Hospital Cancer Center; President and Chief Executive Officer of Dana-Farber Cancer Institute; and Director of Dana-Farber/Brigham and Women's Cancer Center. Daniel A. Haber, MD, PhD, (third photo), is Director of Massachusetts General Hospital Cancer Center.